{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:03:24Z","timestamp":1785017004248,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40120-020-00194-4","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T12:02:42Z","timestamp":1590408162000},"page":"473-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data"],"prefix":"10.1007","volume":"9","author":[{"given":"Sheila R.","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian H.","family":"Tarbox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan S.","family":"Tieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Vera-Llonch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"194_CR1","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23:S107\u2013S112112.","journal-title":"Am J Manag Care"},{"key":"194_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/path.2411","volume":"216","author":"E Ihse","year":"2008","unstructured":"Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol. 2008;216:253\u201361.","journal-title":"J Pathol"},{"key":"194_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jns.2018.09.011","volume":"394","author":"H Koike","year":"2018","unstructured":"Koike H, Nishi R, Ikeda S, et al. The morphology of amyloid fibrils and their impact on tissue damage in hereditary transthyretin amyloidosis: an ultrastructural study. J Neurol Sci. 2018;394:99\u2013106.","journal-title":"J Neurol Sci"},{"key":"194_CR4","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658\u201367.","journal-title":"JAMA"},{"key":"194_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","volume":"47","author":"PN Hawkins","year":"2015","unstructured":"Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47:625\u201338.","journal-title":"Ann Med"},{"issue":"Suppl 1","key":"194_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","volume":"29","author":"Y Parman","year":"2016","unstructured":"Parman Y, Adams D, Obici L, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29(Suppl 1):S3\u201313.","journal-title":"Curr Opin Neurol"},{"key":"194_CR7","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66:2451\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"194_CR8","unstructured":"Rossi K. New program may help cut time to diagnosis for hATTR patients. Rare Disease Report. 2018 Jun 21. https:\/\/www.raredr.com\/news\/new-program-may-help-cut-time-diagnosis-hattr-patients. Accessed 2018 Oct 29."},{"key":"194_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.","journal-title":"Orphanet J Rare Dis"},{"key":"194_CR10","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","volume":"29","author":"D Adams","year":"2016","unstructured":"Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29:S14\u2013S26.","journal-title":"Curr Opin Neurol"},{"key":"194_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/13506129.2011.565524","volume":"18","author":"H Koike","year":"2011","unstructured":"Koike H, Hashimoto R, Tomita M, et al. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid. 2011;18:53\u201362.","journal-title":"Amyloid"},{"key":"194_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","volume":"83","author":"H Koike","year":"2012","unstructured":"Koike H, Tanaka F, Hashimoto R, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry. 2012;83:152\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"194_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","volume":"11","author":"KL McCausland","year":"2018","unstructured":"McCausland KL, White MK, Guthrie SD, et al. Light chain (AL) amyloidosis: the journey to diagnosis. Patient. 2018;11:207\u201316.","journal-title":"Patient"},{"key":"194_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13023-019-1199-x","volume":"14","author":"MP Connolly","year":"2019","unstructured":"Connolly MP, Panda S, Patris J, Hazenberg BPC. Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet J Rare Dis. 2019;14:220.","journal-title":"Orphanet J Rare Dis"},{"key":"194_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mus.26515","volume":"60","author":"A Yarlas","year":"2019","unstructured":"Yarlas A, Gertz MA, Dasgupta NR, et al. Burden of hereditary transthyretin amyloidosis on quality of life. Muscle Nerve. 2019;60:169\u201375.","journal-title":"Muscle Nerve"},{"key":"194_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11\u201321.","journal-title":"N Engl J Med"},{"key":"194_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785\u201392.","journal-title":"Neurology"},{"key":"194_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/TCRM.S219979","volume":"16","author":"M Luigetti","year":"2020","unstructured":"Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109\u201323.","journal-title":"Ther Clin Risk Manag"},{"key":"194_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2147\/CEOR.S207127","volume":"11","author":"TP Quock","year":"2019","unstructured":"Quock TP, Yan T, Tieu R, D\u2019Souza A, Broder MS. Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States. Clinicoecon Outcomes Res. 2019;11:431\u20139.","journal-title":"Clinicoecon Outcomes Res"},{"key":"194_CR20","doi-asserted-by":"crossref","unstructured":"Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data. J Comp Eff Res. 2018. https:\/\/www.futuremedicine.com\/doi\/10.2217\/cer-2017-0100. Accessed 2018 Feb 15.","DOI":"10.2217\/cer-2017-0100"},{"key":"194_CR21","unstructured":"IBM Watson Health\u2122. IBM MarketScan Research Databases for Health Services Researchers. Somers, NY: IBM Corporation; 2019 Apr. https:\/\/www.ibm.com\/downloads\/cas\/6KNYVVQ2. Accesed 29 Oct 2018."},{"key":"194_CR22","unstructured":"Department of Health and Human Services. Protection of Human Subjects. 45. Sect. CFR \u00a746 Oct 1, 2005. https:\/\/www.govinfo.gov\/app\/details\/CFR-2005-title45-vol1\/CFR-2005-title45-vol1-part46. Accesed 1 Apr 2020."},{"key":"194_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613\u20139.","journal-title":"J Clin Epidemiol"},{"key":"194_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"194_CR25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/ajh.24433","volume":"91","author":"MA Gertz","year":"2016","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol. 2016;91:947\u201356.","journal-title":"Am J Hematol"},{"key":"194_CR26","first-page":"178","volume":"32","author":"W Hassan","year":"2005","unstructured":"Hassan W, Al-Sergani H, Mourad W, Tabbaa R. Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Tex Heart Inst J. 2005;32:178\u201384.","journal-title":"Tex Heart Inst J"},{"key":"194_CR27","unstructured":"Schmidt H, Lin H, Agarwal S, et al. Impact of hereditary transthyretin mediated amyloidosis on use of health care services: an analysis of the APOLLO Study. Kumamoto, Japan; 2018. https:\/\/www.alnylam.com\/wp-content\/uploads\/2018\/03\/3.-Healthcare-Burden_FINAL-1.pdf. Accesed 29 Oct 2018."},{"key":"194_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2019.1701429","author":"M In\u00eas","year":"2019","unstructured":"In\u00eas M, Coelho T, Concei\u00e7\u00e3o I, Landeiro F, de Carvalho M, Costa J. Societal costs and burden of hereditary transthyretin amyloidosis polyneuropathy. Amyloid. 2019. https:\/\/doi.org\/10.1080\/13506129.2019.1701429.","journal-title":"Amyloid"},{"key":"194_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/archinternmed.2010.371","volume":"171","author":"KT Unroe","year":"2011","unstructured":"Unroe KT, Greiner MA, Hernandez AF, et al. Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000\u20132007. Arch Intern Med. 2011;171:196.","journal-title":"Arch Intern Med"},{"key":"194_CR30","first-page":"68","volume":"4","author":"SM Dunlay","year":"2011","unstructured":"Dunlay SM, Shah ND, Shi Q, et al. Lifetime costs of medical care after heart failure diagnosis. Circulation. 2011;4:68\u201375.","journal-title":"Circulation"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-020-00194-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-020-00194-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-020-00194-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T11:32:26Z","timestamp":1712835146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-020-00194-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["194"],"URL":"https:\/\/doi.org\/10.1007\/s40120-020-00194-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,25]]},"assertion":[{"value":"19 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}